t(16;21)(q24;q22) in therapy-related acute myelogenous leukemia arising from myelodysplastic syndrome

Paola Dal Cin, Karim Ouahchi

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

Published in Atlas Database: February 2007

Online updated version: http://AtlasGeneticsOncology.org/Reports/1621DalCinID100022.html

DOI: 10.4267/2042/38458

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2007 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics

Age and sex: 32 years old male patient.
Previous History: preleukemia (RAEB diagnosed in 09-2006); Hodgkin's lymphoma diagnosed in 2003.
Organomegally: no hepatomegaly; no splenomegaly; enlarged lymph nodes (History of Hodgkin's lymphoma involving right side neck lymph node); no central nervous system involvement.

Blood

WBC: 0.29 x 10^9/l; Hb: 10.7 g/dl; platelets: 19x 10^9/l.
Bone marrow: Megakaryocytes: none noted; Blasts: 65%; Promyelocytes: 1%; Myeloid Activity: 20%; occasional dysplastic forms; Erythroid Activity: 12%; occasional dysplastic forms; Lymphocytes: 2%.

Cytopathology classification

Cytology: M2 arising from previous myelodysplastic syndrome (RAEB-1).
Immunophenotype: Population of immature cells is positive for CD34+, CD45 (dim), HLA-DR+, CD117+, CD13+, and CD33+ and negative for CD15-, monocytic, B and T lymphoid markers.
Pathology: Involvement by acute myelogenous leukemia (FAB-M2) with background dysmyelopoiesis.

Survival

Date of diagnosis: Hodgkin's lymphoma: (2003);
myelodysplastic syndrome: (09-2006) karyotype was not performed; therapy-related AML: (01-11-2007) karyotype showing t(16;21)
Treatment: Chemotherapy and radiotherapy; chlorambucil, Vinblastine Procarbazine, Prednisone (MOPP) until June 2004; radiotherapy in 2004; ifosfamide, carboplatin and etoposide (ICE) in August 2005; autologous bone marrow transplant in August 2006, and conditioning regimen consisted of Cytoxan, BCNU and etoposide. Induction therapy in January 2007 (16-01-07) and preparation for second transplant.
Complete remission was obtained
Comments: bone marrow biopsy performed on 03-01-2007 showing no evidence of leukemia and 2% of blast. Karyotype performed on bone marrow aspirate was interpreted as 46, XY in 20 metaphases.
Relapse: -
Status: Alive 03-2007

Karyotype

Sample: Bone marrow aspirate; Culture time: 24h;
Banding: GTG.
Results:
49,XY,+Y,+3,+8,t(16;21)(q24;q22)[18]/46,XY[2]
Other molecular cytogenetic technics: FISH evaluation for AML1 rearrangement was performed on abnormal metaphases with the LSI TEL/AML1 ES Dual Color Translocation Probe (Abbott Molecular/Vysis, Inc.).
Other molecular cytogenetics results: Ish der(16)(dimAML1+), der(21)(dimAML1+)[5/5] (see Fig. 2).
The t(16;21) was reported mostly in t-MDS/t-AML, and classified as M2 in a majority of cases. Two cases including this current report were observed after treatment for Hodgkin lymphoma.

Trisomy 8 is a frequent secondary abnormality associated with t(16;21), however in this current case we also report the presence of an additional chromosome Y and trisomy 3.
t(16;21)(q24;q22) in therapy-related acute myelogenous leukemia arising from myelodysplastic syndrome  
Dal Cin P, Ouahchi K

References


This article should be referenced as such: Dal Cin P, Ouahchi K. t(16;21)(q24;q22) in therapy-related acute myelogenous leukemia arising from myelodysplastic syndrome. Atlas Genet Cytogenet Oncol Haematol. 2007;11(3):258-260.